WX: WuXi PharmaTech Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 5:42 PM More on Wuxi Pharmatech (WX): Q1 beats on all fronts as net earnings rose 3.4% Y/Y on strong growth from its China operations. Laboratory-services revenue increased 13%, including revenue growth of 3.8% at its U.S. laboratory services unit, while revenue from the smaller manufacturing-services segment was up 9.6%. For the current quarter, the company expects to earn between $0.30 - $0.40 per ADS, on revenue of $138M to $140M. Analysts were projecting $0.36 per ADS on $142M, respectively. Shares +2.4% AH. Comment! [Healthcare, Global & FX, On the Move, Earnings]
Monday, May 13, 4:55 PM WuXi PharmaTech (WX): Q1 EPS of $0.35 beats by $0.03. Revenue of $131.9M beats by $1.88M. Shares +2.5% AH. (PR) 1 Comment [Earnings, Breaking News, Healthcare, On the Move]
Monday, May 13, 12:10 AM Notable earnings after Monday’s close: HMIN, IOC, SCTY, TRQ, TTWO, VELT, WX Comment! [Earnings]
Sunday, May 12, 5:35 PM Notable earnings after Monday’s close: HMIN, IOC, SCTY, TRQ, TTWO, VELT, WX Comment! [Earnings]
Friday, March 8, 12:25 PM WuXi PharmaTech (WX +3%) moves up on a solid Q4 earnings beat late yesterday. Total revenue jumped 15.8% Y/Y, while net profit rose 1.4% as the drug-research contractor racked up stronger overall sales. For FY13, the company projects an EPS of $1.49 - $1.53 on revenues of $565M -$575M, versus analyst estimates of $1.46 per share on revenues of $570.6M. Comment! [Healthcare, Global & FX, Earnings, On the Move]
Thursday, March 7, 4:50 PM WuXi PharmaTech (WX): Q4 EPS of $0.38 beats by $0.07. Revenue of $125.7M (+15.8% Y/Y) beats by $1.99M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, November 12, 2012, 5:22 PM More on WuXi Pharmatech (WX): Q3 beats on all counts as total revenue jumps 21% Y/Y. Net profit rose 3.2% as margins were boosted by a one-off gain and its top line benefited from higher lab-services revenue. The company also upped the low end of its FY revenue guidance, now seeing revenue coming in between $495M to $498M. For the current quarter, revenue is expected to be around $121M to $124M, shy of the Street's $125M consensus estimate. Comment! [Global & FX, Healthcare, Earnings]
Monday, November 12, 2012, 4:38 PM WuXi PharmaTech (WX): Q3 EPS of $0.36 beats by $0.06. Revenue of $125.8M (+21% Y/Y) beats by $2.5M. (PR) Comment! [Earnings, Healthcare]
Monday, August 13, 2012, 4:34 PM WuXi PharmaTech (WX): Q2 EPS of $0.33 beats by $0.01. Revenue of $130.4M (29+% Y/Y) beats by $4M. Shares +1.9% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Thursday, May 10, 2012, 4:57 PM WuXi PharmaTech (WX): Q1 EPS of $0.33 beats by $0.07. Revenue of $118M (+26.1% Y/Y) beats by $4M. (PR) Comment! [Earnings, Healthcare]
Thursday, March 8, 2012, 4:53 PM WuXi PharmaTech (WX): Q4 EPS of $0.31 beats by $0.05. Revenue of $108.5M (+22.5% Y/Y) beats by $2M. Shares +0.4% AH. (PR) Comment! [Earnings, Healthcare]
Wednesday, September 7, 2011, 11:36 AM The biotech industry looks ripe for more gains after posting a second consecutive year of profits and seeing M&A activity heat up, says Karvy Global Services. Crunching the numbers reveals 8 stocks with implied upside potential based on quarterly results and analyst recommendations. Picks: HITK, CELG, DNDN, WX, TEVA, ILMN, CRL, BIIB. Comment! [Quick Ideas]
Friday, August 12, 2011, 10:27 AM Drug R&D services firm WuXi PharmaTech (WX) is up 2.2% after reporting Q2 revenue of $101.1M (+25% Y/Y) and EPS of $0.29, beating consensus by $2.9M and $0.04. 2011 revenue guidance of $400M-$407M is mostly above a $400.9M consensus. Jeffries is reiterating a Buy, but lowering its PT to $20. (previously) Comment! [Healthcare, Earnings]
Friday, July 30, 2010, 7:15 AM Charles River Laboratories (CRL +6.4%) and Wuxi PharmaTech (WX) call off their merger agreement following continued investor opposition. The $1.6B deal would have been the largest foreign takeover of a Chinese company; instead, Charles River will pay Wuxi a $30M breakup fee and begin a $500M share buyback program. (PR) Comment!
Monday, April 26, 2010, 9:00 AM Premarket gainers: WX +23%. HTZ +13%. WHR +10%. APPY +10%. CRNT +10%. PRWT +9%. BPAX +8%. FBC +8%. DTG +7%. CAR +6%. KERX +5%. MNKD +4%. HUM +4%. CAT +4%.
Losers: CMO -13%. PMI -12%. CKR -4%. Comment!
Monday, April 26, 2010, 7:21 AM Charles River Laboratories (CRL) buys WuXi PharmaTech (WX +8.7%) for $21.25/share, a 28% premium. The roughly $1.6B deal is the largest foreign takeover of a Chinese company and will allow Charles River to expand in China, where revenue from drug-testing services is growing as much as 30% annually. (PR) Comment!

WX WuXi PharmaTech Inc.

WX

WuXi PharmaTech Inc.